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SN-38, an active metabolite of a topoisomerase I inhibitor, CPT-11, exhibits a cyto-
toxic effect by inducing apoptosis in cancer cells.  Phosphatidylinositol-3-OH kinase 
(PI3K)-Akt signaling is known to protect a variety of cells from apoptosis.  The rela-
tionship between resistance to SN-38-induced apoptosis and the PI3K-Akt pathway in 
human gastric cancer cells is unknown.  Here, we did an investigation using two gastric 
cancer cell lines, MKN1 and MKN45.  Cell viability was determined by sodium 3'-[1- 
(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic 
acid hydrate (XTT) assay.  Apoptosis was conﬁrmed by ﬂuorescence microscopy using 
Hoechst 33342 staining.  Expression levels of phospho-Akt (pAkt) were determined by 
Western blotting.  After being treated with SN-38, the populations of sub-G1 cells were 
induced by ﬂow cytometry in 36.8% of MKN45 cells more frequently than in 13.5% of 
MKN1 cells.  SN-38 inhibited the expression of pAkt dose-dependently in MKN45 cells, 
but not in MKN1 cells.  In MKN1 cells, an additional pretreatment with the PI3K inhibi-
tor, LY294002, led to the inhibition of pAkt expression and induced apoptosis.  The re-
sults suggested that SN-38 induces apoptosis by decreasing PI3K-Akt survival signaling, 
the anti-apoptotic signals, in human gastric cancer cells.  Akt inhibitor might be a useful 
anti-tumor agent in combination with CPT-11.
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Gastric cancer continues to be one of the most com-
mon malignancies in Japan.  While the development 
of diagnostic modalities and surgical techniques has 
improved prognosis, the associated mortality is still 
the second highest in Japan after lung cancer (Edi-
torial Board of the Cancer Statistics in Japan, 2003). 
This mortality is due to lack of effective treatment, 
especially in respect to chemotherapy.
Abbreviations:  DMSO, dimethyl sulfoxide;ID80, dose giving 80% inhibition; NF-κB, nuclear factor-κB; pAkt, 
phospho-Akt; PI3K, phosphatidylinositol-3-OH kinase; PIP2, phosphatidylinositol-3,4-bisphosphate; PIP3, phos-
phatidylinositol-3,4,5-trisphosphate; PTEN, phosphatase and tensin homologue deleted on chromosome 10; TopoI, 
topoisomerase I; XTT, sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sul-
fonic acid hydrate 
 New anticancer agents have recently been 
used in gastric cancer therapy.  Camptothecins are 
broad-spectrum anticancer drugs that specifically 
target DNA topoisomerase I (TopoI).  The for-
mation of a cleavable drug-TopoI-DNA complex 
results in lethal double-strand DNA breakage 
and cell death (Xu and Villalona-Calero, 2002). 
CPT-11 is a new semisynthetic derivative of camp-
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tothecin that is ultimately converted into the active 
metabolite SN-38 by carboxylesterase, which is at 
least 100-fold more cytotoxic than CPT-11 (Rokudai 
et al., 2002).  It has also been reported that expo-
sure to camptothecin derivatives induces apoptosis 
(Yoshida et al., 1993) and affects the cell cycle by 
inducing a dose-dependent delay in the S phase 
followed by dose-dependent trapping in the G2/M 
phase (Falk and Smith, 1992). However, the precise 
mechanisms of SN-38-induced apoptosis have not 
been elucidated.
 The phosphatidylinositol-3-OH kinase (PI3K)-
Akt signaling pathway is known to transmit sur-
vival-promoting signals and to protect a variety of 
cells from apoptosis (Franke et al., 1997).  After 
growth factor stimulation, PI3K is activated and 
generates phospholipid second-messenger mol-
ecules, phosphatidylinositol-3,4,5-trisphosphate 
(PIP3) and phosphatidylinositol-3,4-bisphosphate 
(PIP2), which cause a diverse set of cellular re-
sponses.  One target of PI3K is the serine/threonine 
kinase Akt [also known as protein kinase B or 
RAC-PK (Balendran et al., 1999)].  With the gen-
eration of PIP3 and PIP2 proteins by stimulation 
with growth factors and cytokines, Akt is recruited 
to the plasma membrane and is then phosphory-
lated at two key regulatory sites, Thr308 in the ac-
tivation loop of the catalytic domain and Ser473 in 
the COOH-terminal regulatory domain (Alessi et 
al., 1997).  The phosphorylation of Akt at Thr308 
is catalyzed by ubiquitously expressed PDK1 
(Datta et al., 1997; Le et al., 1998; Stephens et al., 
1998).  The kinase responsible for phosphoryla-
tion of Akt at Ser473 was reported to be PDK2 
[PDK1 bound to a fragment of PRK2 (Alessi et al., 
1997)]. Phosphorylation at both residues is neces-
sary for full activation of Akt and the subsequent 
regulation of many cellular processes. Activated 
Akt phosphorylates proapoptotic Bcl-2 family 
member Bad, caspase family member, caspase-9, 
Forkhead family transcription factor, FKHRL1, 
and IκB kinase, leading to cell survival (Kawato et 
al., 1991; Cardone et al., 1998; Brunet et al., 1999; 
Romashkova and Makarov, 1999).  Thus, PI3K-Akt 
signaling pathway inactivation might correlate with 
apoptosis.
 Here, we analyzed SN-38-induced apoptosis 
in human gastric cancer cell lines.  Our data sug-
gest that in some human gastric cancer cells, SN-38 
induces apoptosis, which might be partly explained 
by PI3K-Akt pathway inactivation.
 
Materials and Methods
Cell culture and reagents
MKN1, MKN28, MKN45, MKN74 and KATO-
III cells were purchased from the Riken Cell Bank 
and grown in RPMI-1640 supplemented with 10% 
fetal bovine serum, 100 units/mL of penicillin G 
sodium, 100 µg/mL of streptomycin sulfate and 
0.25 µg/mL of amphotericin B equilibrated with 
5% CO2 in air at 37˚C. SN-38 was obtained through 
Daiichi Pharm (Tokyo, Japan), and LY294002 was 
purchased from Sigma (St. Louis, MO). SN-38 and 
LY294002 were dissolved in dimethyl sulfoxide 
(DMSO).  Dilutions with DMSO were made imme-
diately before use to adjust the DMSO concentration 
in the growth medium to 0.1% for all experiments.
Growth inhibition experiments
The effect of the SN-38 on the proliferation of 
cells was evaluated using the sodium 3'-[1-(phenyl-
aminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-
6-nitro) benzene sulfonic acid hydrate (XTT) assay 
(Cell Proliferation Kit II, XTT; Roche Molecular 
Biochemicals, Mannheim, Germany).  The assay 
is based on the cleavage of the yellow tetrazolium 
salt XTT to form an orange formazan dye by meta-
bolically active cells.  Brieﬂy, cells were seeded into 
96-well plates at a density of 2 × 103 viable cells per 
well in 100 µL medium.  After 24 h incubation, a 
different dose of SN-38 (0–500 nM) was added to 
quadruplicate wells.  Then after 72 h incubation, 50 
µL of the XTT was added to each well (ﬁnal con-
centration 0.3 mg/mL), followed by further incuba-
tion for 4 h in a humidiﬁed atmosphere containing 
5% CO2 at 37˚C.  The absorbance of the samples 
was measured at 490 nm using a microplate reader 
(Wellreader; Seikagaku Corporation, Tokyo, Japan). 
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The dose giving 80% inhibition (ID80) was cal-
culated in terms of the absorbency in treated cells 
relative to the absorbency in untreated control cells.
Cell cycle analysis
Cell cycle distribution was analyzed by determin-
ing the DNA content and the sub-G1 peak corre-
sponding to the apoptotic cells using ﬂow cytom-
etry.  MKN45 (3 × 106) and MKN1 (5 × 105) cells 
were seeded on 75 cm2 tissue culture dishes and 
allowed to grow overnight at 37˚C with 5% CO2. 
Cells were exposed to 50 µM LY294002 for 1 h, 
or not exposed.  Cells were next exposed to 20 nM 
or 250 nM SN-38 for 48 h, then collected, resus-
pended in 70% ethanol and stored at –20˚C until 
use. After ﬁxation, cells were incubated for 20 min 
at 37˚C with RNase A (50 µg/mL) and then for 10 
min at room temperature with propidium iodide (50 
µg/mL).  After samples were ﬁltered through 35-
µm nylon mesh, stained cells were analyzed with 
an FACS Calibur Cytometer (Becton Dickinson, 
Franklin Lakes, NJ).
Detection of apoptotic cells 
Apoptosis was detected morphologically.  Trypsin-
ized adherent and ﬂoating cells were washed with 
phosphate buffered saline and pelleted.  After ﬁxa-
tion with 3.5% formalin solution, apoptotic cells 
were assessed morphologically by staining with 
Hoechist 33342, using ultraviolet laser microscope 
(Optiphoto-2, Nikon, Tokyo).
Western blot analysis
MKN45 and MKN1 cells were treated with LY294002 
and/or SN-38 as in the case for cell cycle analy-
sis.  The cells were lysed in a sample buffer [Tris-
HCl (pH 6.8), SDS, glycerol, bromophenol blue] 
containing protease inhibitor (complete, mini; 
Roche Molecular Biochemicals).  Following soni-
cation, the total protein was quantiﬁed by a BCA 
method (BCA Protein Assay Kit; Pierce, Rockford, 
IL).  Each boiling sample (60 µg protein/lane) was 
separated by 10% SDS-PAGE and blotted onto a 
poly vinilidene difluoride Immobilon membrane. 
The antibodies used in this study were anti-phospho 
Akt (Ser473) polyclonal antibody (#9271, Cell Sig-
naling Technology, Beverly, MA), anti-phosphatase 
and tensin homologue deleted on chromosome 10 
(PTEN) polyclonal antibody (#21940, Upstate Cell 
Signaling Solutions, Charlottesville, VA) and anti-
β-actin monoclonal antibody (AC-15, Sigma).  
Results
The effect of SN-38 on cell viability and 
apoptosis in MKN1 and MKN45 cells
We ﬁrst examined the susceptibility of the two hu-
man gastric cancer cell lines, MKN1 and MKN45, 
to SN-38 treatment.  Figure 1 shows the dose-
dependent cytotoxic effect of SN-38 against MKN1 
and MKN45 cells using an XTT cell proliferation 
assay kit.  The ID80s of MKN45 and MKN1 cells 
were 20 nM and 250 nM, respectively.  We also ex-
amined the susceptibility of three other human gas-
tric cancer cell lines, MKN74, MKN28 and KATO-
III cells.  ID80s of MKN74, MKN28 and KATO-III 
cells were 15 nM, 200 nM and 30 nM, respectively. 
MKN45, MKN74 and KATO-III cells showed high 
sensitivity to SN-38 (ID80 < 50 nM), and MKN1 
and MKN28 cells showed low sensitivity to SN-38 
(ID80 > 100 nM).  Then we used MKN45 and 
Fig. 1.  XTT assay of MKN1 and MKN45 cells treated 
with SN-38. The rates of MKN1 cells are shown by open 
circles, and those of MKN45 cells, by closed circles.
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MKN1 cells as the representative cell lines for the 
following studies.
 Then, we examined the effect on the cell cycle 
in MKN1 and MKN45 cells after SN-38 treat-
ment using ﬂ ow cytometry.  An evident apoptotic 
sub-G1 fraction was shown in MKN45 cells 48 
h after treatment with 250 nM SN-38 (Fig. 2A). 
We further confirmed SN-38-induced apoptosis 
of MKN45 cells morphologically by fluorescence 
microscopy with a Hoechst 33342:  250 nM SN-38 
induced apoptosis in MKN45 cells, in which there 
were condensed and fragmented nuclei (Fig. 2B). 
However, MKN1 cells treated with 250 nM SN-38 
suffered delays in the S phase (Fig. 3A) and had a 
few apoptotic cells (Fig. 3B).  As shown in Fig. 4, 
the apoptotic sub-G1 fractions of the population of 
MKN45 and MKN1 cells 48 h after treatment with 
250 nM SN-38 were 36.8 and13.5%, respectively.  
pAkt and PTEN expression after treatment 
with SN-38 in gastric cancer cell lines
Next, we examined pAkt and PTEN expression 
after treatment with SN-38 by Western blotting.  In 
MKN45 cells, the expression levels of pAkt were 
reduced in a dose-dependent manner by SN-38 
(Fig. 5).  On the other hand, the expression levels of 
pAkt were not affected by SN-38 in MKN1 cells. 
The expression levels of PTEN were not affected in 
either cell line (Fig. 5).
Fig. 2.  Apoptosis of MKN45 cells by SN-38.  
 A: Flow cytometry of MKN45 cells treated with 20 nM or 250 nM SN-38 for 48 h.  
 B: Fluorescent microscopy of MKN45 cells treated with 250 nM SN-38 for 48 h, and stained with Hoechst 
33342 ﬂ uorescent dye.
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PI3K inhibitor reduced the expression level 
of pAkt and induced apoptosis in MKN1 cells 
Through SN-38 treatment, pAkt expression in 
MKN45 cells was reduced but not in MKN1 cells 
while MKN45 cells have a higher sensitivity to 
SN-38 than MKN1 cells.  To elucidate that the 
PI3K-Akt pathway is involved in SN-38-induced 
apoptosis, we examined whether LY294002 could 
affect SN-38-induced apoptosis in MKN1 cells. 
LY294002 is a speciﬁ c PI3K inhibitor that has been 
widely used to study the role of PI3K in various 
biological responses.
 The expression level of pAkt in MKN1 cells 
reduced in an SN-38 dose-dependent manner after 
Fig. 3.  Inﬂ uence of SN-38 to MKN1 cells. 
 A: Effect of 20 nM or 250 nM SN-38 on the cell cycle progression of MKN1 cells after 48 h incubation deter-
mined by ﬂ ow cytometry. 
 B: Fluorescence microscopy dyeing, Hoechst 33342 after 250 nM SN-38 treatment for 48 h.
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Fig. 4.  Sub-G0G1 population in MKN45 and MKN1 
cells treated with 0, 20 or 250 nM SN-38 for 48 h. 
*P < 0.05 using Student sʼ t-test.
A
Control
SN-38
 20 nM
SN-38
250 nM
B
Control
SN-38
250 nM
11
SN-38-induced apoptosis in gastric cancer
pretreatment with 50 µM LY294002 (Fig. 6).  We 
also examined PTEN expression using Western 
blotting, but LY294002 had no inﬂuence on PTEN 
expression (Fig. 6).
 Moreover, by cell cycle analysis, the apoptotic 
sub-G1 fraction appeared by ﬂow cytometry (Fig. 
7A). By morphological examination, apoptotic 
cells were increased by treatment with SN-38 and 
LY294002 (Fig. 7B).  The apoptotic sub-G1 frac-
tion of the population of MKN1 cells was 35.9% 
48 h after treatment with 250nM SN-38 and 50 µM 
LY294002 (Fig. 8).  Exposure to 50 µM LY294002 
increased SN-38-induced apoptosis in MKN1 cells 
to as much as that in MKN45 cells after treatment 
with only SN-38 (Fig. 8).  These results indicated 
that the PI3K-Akt pathway plays a signiﬁcant role 
in SN-38-induced apoptosis in human gastric can-
cer cells.
 
Fig. 5.  Western blotting of pAkt and PTEN expression after 0, 5, 10, 20, 100 or 250 nM SN-38 treatment for 48 h.
Fig. 6.  Western blot of pAkt and PTEN expression. 
MKN1 cells were treated with 0, 20 or 250 nM SN-38 
for 48 h in the presence of 50 µM LY294002. 
 
Discussion
The MKN45 cells were more sensitive to SN-38 
than the MKN1 cells.  The difference of sensitiv-
ity mainly comes from the percentage of apoptotic 
cells.  The pattern of tumor response after in vivo 
topotecan treatment was reported to correlate with 
the ability of the drug to induce apoptosis but not 
with its in vitro antiproliferative activity (Caserini 
et al., 1997).  Apoptosis is a major mode of cell 
death in response to chemotherapeutic drug treat-
ment (Hickman, 1992; Kerr et al., 1994), and 
resistance to apoptosis induction has been pro-
posed as a critical mechanism in drug resistance 
(Kataoka et al., 1994; Chen et al., 1996; Seimiya 
et al., 1997).  However, the mechanisms by which 
chemotherapeutic agents induce apoptosis are not 
fully understood.  The sensitivity of cells to che-
motherapeutic drug-induced apoptosis appears to 
depend on the balance between proapoptotic and 
antiapoptotic signals.  Therefore, it is possible that 
a chemotherapeutic drug may induce apoptosis not 
only by increasing the proapoptotic signals but also 
by decreasing the antiapoptotic ones.
 The PI3K-Akt signaling pathway is known to 
transmit survival signals and to protect a variety 
of cells from apoptosis.  Akt plays a critical role in 
controlling the balance between cell survival and 
apoptosis (Balendran et al., 1999).  Phosphoryla-
tion of Akt is promoted by phosphatidylinositides 
converted by PI3K products.  Previous reports have 
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Fig. 7.  Inﬂ uence of LY294002 to MKN1cells. 
 A:  Cell cycle analysis by ﬂ ow cytometry. 
 B:  Morphological detect ion of apoptosis by 
Hoechst 33342 staining. 
Fig. 8.  Sub-G0G1 population in MKN45 and MKN1 
cells treated with 0, 20 or 250 nM SN-38 in the presence 
or absence of LY294002 for 48 h. *P < 0.05 using Stu-
dent sʼ t-test.
shown that Akt delivers antiapoptotic survival 
signals by phosphorylating Bad and activating cas-
pase-9 (Cardone et al., 1998; Brunet et al., 1999). 
In addition, inhibition of Akt signaling can induce 
apoptosis in some human cancer cell lines (Page 
et al., 2000; Yuan et al., 2000).  It has also been 
reported that Akt plays an important role in cell 
survival when cells are exposed to different apop-
totic stimuli, such as growth factor withdrawal, 
ultraviolet radiation, matrix detachment, cell cycle 
discordance and DNA damage (Hemmings, 1997; 
Kulik et al., 1997; Kulik and Weber, 1998; Ng et 
al., 2000; Brognard et al., 2001).  Moreover, in-
activation of PI3K using a specific inhibitor has 
led to dephosphorylation of Akt at Ser473, con-
sequently causing translocation of Akt to nuclei, 
A
 DMSO LY294002 50 µM
 LY294002 50 µM LY294002 50 µM
 + +
 SN-38 20 nM SN-38  250 nM
  
B
LY294002 50 µM
LY294002 50 µM + SN-38 250 nM
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where it is believed to regulate the transcription of 
genes mediating cell survival or apoptosis (Hem-
mings, 1997).  In a previous study, TRAIL and Fas 
induced apoptosis by inhibition of the PI3K-Akt 
pathway in human gastric cancer cells (Nam et al., 
2003; Osaki et al., 2004).  Our study showed that 
apoptosis was induced in cells where pAkt expres-
sion was reduced (MKN45), but not in cells where 
pAkt expression showed no change (MKN1) by 
SN-38.  It has been reported that exposure to camp-
tothecin induced a dose-dependent trapping in the 
G2/M phase affects and dose-dependent delay in 
the S phase.  Treatment of MKN1 cells with 48 h 
20 nM SN-38 induced G2/M phase arrest, and 48 
h 250 nM SN-38 treatment induced S phase delay. 
Meanwhile in MKN45 cells, 48 h 20 nM SN-38 
treatment induced G2/M phase arrest tendency 
and 48 h 250 nM SN-38 treatment induced sub-G1 
peak.  We speculate that low dose SN-38 treatment 
below 20 nM induces the G2/M arrest in MKN45 
cells and 20 nM SN-38 treatment begins to induce 
S phase cells.  Moreover, in MKN45 cells, 250 nM 
SN-38 treatment induces apoptosis by reducing 
pAkt expression but MKN1 cells showed resistance 
for apoptosis by no change in pAkt expression.
 Therefore, inactivation of pAkt using the PI3K 
inhibitor, LY294002, finally induced apoptosis 
in MKN1 cells as well as in only SN-38-treated 
MKN45 cells.  It was also reported (Nakashio et 
al., 2000) that constitutively active Akt results in 
a reduction of the cytotoxic effect of topotecan 
in lung carcinoma cells.  The PI3K-Akt pathway 
might thus play a signiﬁcant role in SN-38-induced 
apoptosis in human gastric cancer cells.
 The tumor suppression gene PTEN is a natu-
ral biological inhibitor of Akt cell survival signals. 
PTEN expression sensitizes cells to death receptor-
mediated apoptosis induced by a variety of stimuli, 
such as tumor necrosis factor (Mayo et al., 2002), 
TRAIL (Thakkar et al., 2001) and chemotherapeu-
tic agents (Tanaka et al., 2000).  Akt is abnormally 
activated in several human tumors by loss of PTEN 
(Di Cristofano and Pandolfi, 2000; Simpson and 
Parsons, 2001).  Recent studies have documented 
that PTEN appears to negatively regulate PI3K-Akt 
survival signaling by removing the D-3 phosphate 
from PIP3, which is a primary activator of Akt 
(Maehata and Dixon, 1998).  Loss of PTEN results 
in high basal activity of Akt in a variety of tumors, 
while introduction of PTEN suppresses the activity. 
It is reported (Saga et al., 2002) that overexpression 
of PTEN increased sensitivity to SN-38 in ovarian 
cancer cells.  However, in our study, the expression 
of PTEN was not correlated with SN-38-induced 
apoptosis; in human gastric cancer cells, SN-38 
might suppress the PI3K-Akt signaling via a PTEN 
independent pathway.  Rokudai et al. (2002) re-
ported that suppression of PDK1, but not of PI3K, 
was one of the mechanisms of chemotherapeutic 
drug-mediated Akt inactivation, because VP-16 
indirectly suppressed PDK1 kinase activity in 293T 
cells.  However, the mechanisms of SN-38-medi-
ated Akt inactivation remain unclear.  Overexpres-
sion of constitutive active Akt using a transfected 
active form of akt cDNA overcame chemotherapeu-
tic drug-induced apoptosis.  Akt inactivation might 
be a sign of chemotherapeutic drug sensitivity of 
cancer cells, because it was found only in chemo-
sensitive cells (MKN45).
 Nuclear factor-κB (NF-κB) is a ubiquitously 
expressed transcription factor involved in a wide 
spectrum of cellular functions like cell cycle con-
trol, stress adaptation, inﬂammation and control of 
apoptosis (Pahl, 1999).  NF-κB is constitutively ac-
tivated in various types of tumors, including gastric 
cancer (Sasaki et al., 2001).  Several investigators 
have reported that inhibition of the NF-κB pathway 
by adenoviral delivery of an IκBα superrepressor, 
small interfering RNA, against the p65 subunit of 
NF-κB or TNFα increased SN-38-induced apopto-
sis (Camp et al., 2004; Guo et al., 2004; Valente et 
al., 2003).  Besides the PI3K-Akt pathway, the NF-
κB pathway might also facilitate an antiapoptotic 
signal to inhibit SN-38-induced apoptosis.
 In conclusion, we found that SN-38 induced 
apoptosis by decreasing the PI3K-Akt survival sig-
naling, the antiapoptotic signals in human gastric 
cancer cells.  A selective small molecule inhibitor 
of Akt, the Akt/protein kinase B signaling inhibi-
tor-2 (API-2) was recently discovered by screening 
the National Cancer Institute Diversity Set (Yang et 
al., 2004).  Such an Akt inhibitor might be a useful 
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anti-tumor agent in combination with a chemother-
apeutic agent, such as CPT-11.
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